Haemonetics Corporation (HAE) — Fair Value Analysis
Base-case fair value (P50): $96.20 · Current price: $73.08 · Verdict: Undervalued
The Verdict on HAE
Monte Carlo simulations suggest HAEMONETICS CORP (HAE) is currently undervalued, presenting a notable opportunity for investors. With the stock trading at $73.08, our analysis indicates a median fair value (P50) of $96.20. This implies a significant +31.6% potential upside from its current trading level, suggesting the market may not be fully appreciating HAE's underlying value based on its long-term financial prospects and operational health. The discrepancy between the current price and the simulated fair value highlights a compelling entry point for those looking to capitalize on HAE's potential.
How HAE stacks up against peers
While HAEMONETICS CORP operates without a specified sector in our current data, its quality tier is assessed as "average" when evaluating its operational and financial health against its broader market context. This "average" quality tier suggests a stable foundation, but the substantial +31.6% to our $96.20 fair value indicates that even with this operational standing, HAE's intrinsic value isn't fully reflected in its $73.08. This robust upside, derived from a comprehensive simulation of future financial scenarios, distinguishes HAE as a potential performer that is not yet recognized by the broader market.
What this means for investors
For investors, the +31.6% gap between HAE's $73.08 and its $96.20 fair value signals a strong buy signal according to our Monte Carlo models. The "average" quality tier suggests a resilient business that, despite potential sector-specific challenges, possesses the fundamentals to warrant a higher valuation. The significant projected upside points to a scenario where HAEMONETICS CORP's stock could appreciate substantially, aligning closer to its calculated intrinsic value. To fully understand the range of potential outcomes, including both downside and bull case scenarios, sign up for FairCurve to see the full bear/bull distribution and track HAE's fair value as new fundamentals are released.
Frequently Asked Questions
Is HAE overvalued or undervalued right now?
HAEMONETICS CORP (HAE) is currently considered undervalued. Our median fair value (P50) is $96.20, which is notably higher than its current trading price of $73.08.
What is the bear case and bull case for HAE?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is exclusively available with a free FairCurve account. This provides a comprehensive view beyond the median fair value.
How does FairCurve calculate HAE's fair value?
FairCurve calculates HAE's fair value using Monte Carlo simulations, running thousands of forward-looking financial scenarios. This robust methodology accounts for various market and company-specific variables to determine a probabilistic range of intrinsic values.
How can I track HAE's fair value as it changes?
To track HAE's fair value, add the ticker to a free FairCurve watchlist. You'll receive daily fair-value updates and instant re-valuation alerts whenever new earnings reports or significant fundamental data are released.